Acute Myocardial Infarction (AMI)Early AMI-CMRNCT07602439
Early CMR in Acute MI
An observational study of Acute Myocardial Infarction (AMI), run by The Affiliated Hospital of Xuzhou Medical University at 1 site in China.
Trial summary
The goal of this observational study is to evaluate the clinical utility of cardiac magnetic resonance (CMR) in patients with acute myocardial infarction (AMI). This is a retrospective and prospective cohort study that has already enrolled a number of patients and will continue to enroll additional patients on a… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction (AMI)
- What is being tested?
- Cardiac magnetic resonance imaging
- How many people
- 2,000 participants
- Where
- 1 siteChina
- Study dates
- 31 Oct 2018to 23 Mar 2046
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with AMI and who underwent CMR within the acute phase of symptom onset.
Who may be able to join
- Patients aged 18 years or older.
- Patients diagnosed with acute myocardial infarction.
- Patients who complete cardiovascular magnetic resonance imaging during the acute phase after symptom onset.
- Patients with available clinical, CMR, and follow-up data.
Who cannot join
- History of previous myocardial infarction.
- Severe renal insufficiency, defined as estimated glomerular filtration rate <30 mL/min/1.73 m².
- Presence of malignant tumors.
- Poor CMR image quality unsuitable for analysis.
Trial locations and contacts
1 site in 1 country.
China1 site
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221000
About this study
Official title: Exploring the Application and Value of Cardiac Magnetic Resonance in Acute Myocardial Infarction
The goal of this observational study is to evaluate the clinical utility of cardiac magnetic resonance (CMR) in patients with acute myocardial infarction (AMI). This is a retrospective and prospective cohort study that has already enrolled a number of patients and will continue to enroll additional patients on a rolling basis.
The main question it aims to answer is:
Read more
How does CMR, performed acute phase, contribute to risk stratification, prognostic assessment, and long-term clinical management in patients with AMI?
Participants who have had an AMI will undergo CMR within one week of symptom onset. After discharge, they will be regularly followed up at 1, 3, 6, 9, and 12 months, and then every 6 months thereafter. Clinical outcomes will be collected during each follow-up visit.
Read the detailed description
This is an ambispective observational cohort study. The study will include patients who have already undergone CMR examination and meet the eligibility criteria, as well as consecutively enrolled patients who will undergo CMR during the prospective study period.
- Conditions
- Acute Myocardial Infarction (AMI)
- Being tested
- Cardiac magnetic resonance imaging
- Keywords
- AMI, CMR
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardiac magnetic resonance imagingOther
Cardiovascular magnetic resonance imaging will be used to assess cardiac structure, function, myocardial injury, infarct size, late gadolinium enhancement, microvascular obstruction, and other CMR-derived parameters. This is an observational cohort study, and no diagnostic test or treatment will be assigned by the investigators. CMR examinations have been or will be performed as part of routine clinical evaluation according to clinical indications.
| Study group | Role | What they receive |
|---|---|---|
| AMI | Not described Receives: Other: Cardiac magnetic resonance imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major Adverse Cardiovascular Events (MACE)
A composite of cardiovascular death, non-fatal myocardial infarction, unplanned coronary revascularization, and hospitalization for heart failure. Assessed from the date of index hospitalization through the end of follow-up.
Measured: through study completion, an average of 5 years
Secondary outcomes (1)
Cardiac Magnetic Resonance (CMR) Imaging Parameters
Presence of microvascular obstruction assessed by late gadolinium enhancement cardiovascular magnetic resonance imaging.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start31 Oct 2018
- Primary completion23 Mar 2046 (estimated)
- Study completion23 Mar 2046 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07602439
- Sponsor's protocol ID
- XYFY2026-KL154-01
- Acronym
- Early AMI-CMR
- Status last verified
- May 2026
- First submitted
- 22 Mar 2026
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Application and Value of Cardiac Magnetic Resonance in Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT07602439
- Acronym / sponsor ID
- Early AMI-CMR / XYFY2026-KL154-01
- Conditions
- Acute Myocardial Infarction (AMI)
- Keywords
- AMI, CMR
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- The Affiliated Hospital of Xuzhou Medical UniversityUniversity, hospital or other
- Study start
- 31 Oct 2018 (actual)
- Primary completion
- 23 Mar 2046 (estimated)
- Study completion
- 23 Mar 2046 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate the clinical utility of cardiac magnetic resonance (CMR) in patients with acute myocardial infarction (AMI). This is a retrospective and prospective cohort study that has already enrolled a number of patients and will continue to enroll additional patients on a rolling basis.
The main question it aims to answer is:
How does CMR, performed acute phase, contribute to risk stratification, prognostic assessment, and long-term clinical management in patients with AMI?
Participants who have had an AMI will undergo CMR within one week of symptom onset. After discharge, they will be regularly followed up at 1, 3, 6, 9, and 12 months, and then every 6 months thereafter. Clinical outcomes will be collected during each follow-up visit.
Detailed description
This is an ambispective observational cohort study. The study will include patients who have already undergone CMR examination and meet the eligibility criteria, as well as consecutively enrolled patients who will undergo CMR during the prospective study period.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AMI | – | Other: Cardiac magnetic resonance imaging |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with AMI and who underwent CMR within the acute phase of symptom onset.
Key inclusion criteria (4 listed)
- Patients aged 18 years or older.
- Patients diagnosed with acute myocardial infarction.
- Patients who complete cardiovascular magnetic resonance imaging during the acute phase after symptom onset.
- Patients with available clinical, CMR, and follow-up data.
Key exclusion criteria (4 listed)
- History of previous myocardial infarction.
- Severe renal insufficiency, defined as estimated glomerular filtration rate <30 mL/min/1.73 m².
- Presence of malignant tumors.
- Poor CMR image quality unsuitable for analysis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cardiac magnetic resonance imagingCardiovascular magnetic resonance imaging will be used to assess cardiac structure, function, myocardial injury, infarct size, late gadolinium enhancement, microvascular obstruction, and other CMR-derived parameters. This is an observational cohort study, and no diagnostic test or treatment will be assigned by the investigators. CMR examinations have been or will be performed as part of routine clinical evaluation according to clinical indications. | Other | AMI |
Primary outcome
Major Adverse Cardiovascular Events (MACE)
Time frame: through study completion, an average of 5 years
A composite of cardiovascular death, non-fatal myocardial infarction, unplanned coronary revascularization, and hospitalization for heart failure. Assessed from the date of index hospitalization through the end of follow-up.
1 secondary outcome
Cardiac Magnetic Resonance (CMR) Imaging Parameters
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Myocardial Infarction (AMI)
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
RecruitingObservational study
Cardiogenic Shock Working Group Registry
Cardiogenic Shock
RecruitingObservational study
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
AMI Cardiogenic Shock
RecruitingObservational study
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
Heart Failure, Muscle Atrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction (AMI), run by The Affiliated Hospital of Xuzhou Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major Adverse Cardiovascular Events (MACE) (time frame: through study completion, an average of 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.